Critical appraisal of 3-monthly paliperidone depot injections in the treatment of schizophrenia
Bernardo Carpiniello, Federica Pinna Department of Public Health, Clinical and Molecular Medicine – Psychiatry Research Unit and Psychiatric Clinic, University Hospital, Cagliari, Italy Aims: Three-monthly injections of paliperidone palmitate (PP-3M) represent a new and recently introduced...
Saved in:
Main Authors: | Carpiniello B (Author), Pinna F (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2016-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A critical appraisal of paliperidone long-acting injection in the treatment of schizoaffective disorder
by: Chue P, et al.
Published: (2016) -
Comparative effectiveness study of paliperidone palmitate 6-month with a real-world external comparator arm of paliperidone palmitate 1-month or 3-month in patients with schizophrenia
by: Ibrahim Turkoz, et al.
Published: (2023) -
Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation
by: Olivier Corbeil, et al.
Published: (2022) -
Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan
by: Mahlich J, et al.
Published: (2015) -
Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate
by: Charmi Patel, et al.
Published: (2019)